Navigation Links
SYNARC Appoints Ciaran Cooper as Vice President, Business Development
Date:2/9/2011

SAN FRANCISCO, Feb. 9, 2011 /PRNewswire/ -- SYNARC, the world's leading provider of medical image analysis services to the pharmaceutical and biotechnology industries, announced today that Ciaran Cooper has joined SYNARC to lead the sales and marketing efforts in support of the company's rapidly growing business in imaging services for clinical trials.

Ciaran Cooper, a pioneer in the clinical trials imaging services industry, brings over 20 years experience in medical imaging with an emphasis in business development, strategic planning, and management. He co-founded MIICRO, Inc. in 1994, the first imaging CRO specialized in early phase translational imaging with FDG PET. Since then, Cooper has worked for several imaging core labs as a senior manager in business development and thus brings with him a vast knowledge of various business models, therapeutic areas, and growth strategies.

"I'm thrilled to be joining SYNARC at this exciting time in their development," said Cooper. "SYNARC has always maintained a reputation for science-led, high quality service across a range of therapeutic areas and indications. In the last several years, they have successfully expanded their focus to include oncology and cardiology on top of their historic dominance in musculoskeletal and neurology – few people know how much oncology and cardiology work SYNARC is already engaged in; that's an exciting message to carry out to our customers. To be surrounded by so many bright minds all focused on delivering the highest level of quality to our customers is a dream come true. I'm really proud to be a part of this team."

Aaron Timm, Head of Imaging for CCBR-SYNARC, stated, "Ciaran offers us a very unique perspective on the industry. He has a vast knowledge of the imaging service arena and his reputation for hard work, creativity, and integrity fit well with our team. We're very happy to welcome him aboard."

About CCBR-SYNARC

CCBR-SYNARC's medical image analysis, biochemical marker, and clinical research center services enable life-science industry clients to execute clinical trials accurately while decreasing the time, uncertainty, and cost of product development. CCBR-SYNARC has partnered with industry leaders to bring numerous leading compounds to market across a broad spectrum of therapeutic areas. Our services integrate critical aspects of clinical-trial design and execution, from protocol design and subject recruitment to regulatory liaison on behalf of our clients.  Our expert radiologists and scientists are innovators in all aspects of medical image analysis and biochemical markers in drug development, and have pioneered many methods used in today's clinical trials.Media Contact:Joy Valderrama 415 817-8919 joy.valderrama@synarc.com(Logo: http://photos.prnewswire.com/prnh/20110113/SF29497LOGO)


'/>"/>
SOURCE SYNARC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CCBR-SYNARC Expands Electronic Data Capture Capabilities
2. Quark Pharmaceuticals Appoints New Chief Medical Officer
3. West Pharmaceutical Services, Inc. Appoints New Director
4. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
5. Curemark Appoints Preeminent Pediatrics Gastroenterologist
6. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
7. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
8. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
9. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
10. NovaRx Appoints Industry Veteran as President and COO
11. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... 29, 2017  Maxor National Pharmacy Services, LLC ("Maxor"), ... has named Leah Bailey as General Counsel.  Bailey ... the company. With more than 13 years ... years focused on health care, Bailey joins the Maxor ... Prime, Bailey advised the PBM, Specialty, and Mail Order ...
(Date:3/29/2017)... Varian Medical Systems (NYSE: VAR ) ... quarter of fiscal year 2017 following the close of regular ... be followed by a teleconference available to all interested parties ... to the conference call webcast will be available on the ... call and replay: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 30, 2017 , ... Grass pollen is the main cause of hay fever in the United ... for grass pollen runs from May to July each year; with the worst time for ... HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they ...
(Date:3/29/2017)... ... ... Brand EXOUS Bodygear announced today a special sale price for the EX-701 Knee ... the price will be only $19.97. The EXOUS Bodygear 65cm exercise ball ... $19.97). , The special promotional prices are to help individuals get their products at ...
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... Minn. (PRWEB) , ... March 29, 2017 , ... ... medical office buildings (MOBs) and other outpatient facilities, and who are the most ... exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found that ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar ... at 1:00 PM ET. A recording of the webinar will also be made available ... Home health and hospice companies are still popular targets for healthcare investors. This highly ...
Breaking Medicine News(10 mins):